InMed Pharmaceuticals (INM) Price & Analysis

Q: What was InMed Pharmaceuticals’s price range in the past 12 months?

InMed Pharmaceuticals lowest stock price was $1.13 and its highest was $8.27 in the past 12 months.

Q: What is InMed Pharmaceuticals’s market cap?

InMed Pharmaceuticals’s market cap is $3.45M.

Q: When is InMed Pharmaceuticals’s upcoming earnings report date?

InMed Pharmaceuticals’s upcoming earnings report date is Feb 13, 2026 which is in 48 days.

Q: How were InMed Pharmaceuticals’s earnings last quarter?

InMed Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.437 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.437.

Q: Is InMed Pharmaceuticals overvalued?

According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does InMed Pharmaceuticals pay dividends?

InMed Pharmaceuticals does not currently pay dividends.

Q: What is InMed Pharmaceuticals’s EPS estimate?

InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does InMed Pharmaceuticals have?

InMed Pharmaceuticals has 2,804,186 shares outstanding.

Q: What happened to InMed Pharmaceuticals’s price movement after its last earnings report?

InMed Pharmaceuticals reported an EPS of -$0.437 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.

Q: Which hedge fund is a major shareholder of InMed Pharmaceuticals?

Currently, no hedge funds are holding shares in INM

Compare

385 Followers

INM Stock Chart & Stats

$1.23

-$0.34(-7.10%)

At close: Jan 08 4:00 PM EST

$1.23

-$0.34(-7.10%)

Day’s Range― - ―

52-Week Range$1.13 - $8.27

Previous CloseN/A

Volume49.03K

Average Volume (3M)113.41K

Market Cap

$3.45M

Enterprise Value-$3.87M

Total Cash (Recent Filing)$9.37B

Total Debt (Recent Filing)$215.48M

Price to Earnings (P/E)―

Beta3.43

Next Earnings

Feb 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding2,804,186

10 Day Avg. Volume156,716

30 Day Avg. Volume113,414

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.24

Price to Sales (P/S)0.64

P/FCF Ratio-0.56

Enterprise Value/Market Cap-1.12

Enterprise Value/Revenue-0.73

Enterprise Value/Gross Profit-2.12

Enterprise Value/Ebitda0.48

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Sell

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

InMed Pharmaceuticals News

InMed Shareholders Approve Directors and Equity Financing Flexibility

InMed Pharmaceuticals ( ($INM) ) has provided an announcement. On December 17, 2025, InMed Pharmaceuticals held its 2025...

9d ago

INM

InMed Faces Challenges from New U.S. Legislation

InMed Pharmaceuticals ( ($INM) ) has issued an announcement. On December 12, 2025, InMed Pharmaceuticals announced that the...

12d ago

INM

InMed Pharmaceuticals Completes Key Study for INM-901

InMed Pharmaceuticals ( ($INM) ) just unveiled an announcement. On November 18, 2025, InMed Pharmaceuticals announced the successful...

1M ago

INM

InMed announces completion of pharmacokinetic studies for Alzheimer’s candidate

InMed Pharmaceuticals (INM) announced the “successful” completion of pharmacokinetic studies in large animal models for its Alzheimer’s disease...

1M ago

INM

InMed Completes Key Pharmacokinetic Studies for Alzheimer’s Candidate INM-901

InMed Pharmaceuticals ( ($INM) ) has provided an update. InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies...

1M ago

INM

InMed Pharmaceuticals Reports Q3 2025 Financial Results

Inmed Pharmaceuticals Inc. ( ($INM) ) has released its Q1 earnings. Here is a breakdown of the information...

1M ago

INM

InMed Pharmaceuticals Advances Alzheimer’s Program Amidst Strong Fiscal Start

The latest announcement is out from InMed Pharmaceuticals ( ($INM) ). InMed Pharmaceuticals reported its first quarter fiscal...

2M ago

INM

InMed Pharmaceuticals Strengthens Board with Strategic Appointment

InMed Pharmaceuticals ( ($INM) ) has issued an announcement. InMed Pharmaceuticals has appointed Mr. John Bathery to its...

2M ago

INM

InMed Pharmaceuticals Strengthens Board with Appointment of Industry Veteran Neil Klompas

An update from InMed Pharmaceuticals ( ($INM) ) is now available. InMed Pharmaceuticals has appointed Mr. Neil Klompas...

3M ago

INM

InMed Pharmaceuticals: Advancing Cannabinoid-Based Therapies

Inmed Pharmaceuticals Inc. ( ($INM) ) has released its Q4 earnings. Here is a breakdown of the information...

3M ago

INM

Trump links Tylenol use to autism, AutoZone reports downbeat Q4: Morning Buzz

The major averages were mixed near noon as traders continue to monitor the recent market rally, as well...

3M ago

InMed Pharmaceuticals Advances Alzheimer’s Program with Promising Results

An announcement from InMed Pharmaceuticals ( ($INM) ) is now available. InMed Pharmaceuticals reported its fiscal year 2025...

3M ago

INM

InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year

Reports FY25 revenue $4.9M vs $4.6M last year. The Company expects its cash will be sufficient to fund...

3M ago

INM

InMed Pharmaceuticals files to sell 3.9M common shares for holders

17:29 EDT InMed Pharmaceuticals (INM) files to sell 3.9M common shares for holders Published first on TheFly –...

6M ago

INM

INM FAQ

What was InMed Pharmaceuticals’s price range in the past 12 months?

InMed Pharmaceuticals lowest stock price was $1.13 and its highest was $8.27 in the past 12 months.

What is InMed Pharmaceuticals’s market cap?

InMed Pharmaceuticals’s market cap is $3.45M.

When is InMed Pharmaceuticals’s upcoming earnings report date?

InMed Pharmaceuticals’s upcoming earnings report date is Feb 13, 2026 which is in 48 days.

How were InMed Pharmaceuticals’s earnings last quarter?

InMed Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.437 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.437.

Is InMed Pharmaceuticals overvalued?

According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InMed Pharmaceuticals pay dividends?

InMed Pharmaceuticals does not currently pay dividends.

What is InMed Pharmaceuticals’s EPS estimate?

InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InMed Pharmaceuticals have?

InMed Pharmaceuticals has 2,804,186 shares outstanding.

What happened to InMed Pharmaceuticals’s price movement after its last earnings report?

InMed Pharmaceuticals reported an EPS of -$0.437 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of InMed Pharmaceuticals?

Currently, no hedge funds are holding shares in INM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.